Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.
Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Parseghian CM, et al. Among authors: napolitano s. Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509. Ann Oncol. 2019. PMID: 30462160 Free PMC article.
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Napolitano S, Matrone N, Muddassir AL, Martini G, Sorokin A, De Falco V, Giunta EF, Ciardiello D, Martinelli E, Belli V, Furia M, Kopetz S, Morgillo F, Ciardiello F, Troiani T. Napolitano S, et al. J Exp Clin Cancer Res. 2019 Dec 16;38(1):492. doi: 10.1186/s13046-019-1497-0. J Exp Clin Cancer Res. 2019. PMID: 31842958 Free PMC article.
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.
Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Parseghian CM, et al. Among authors: napolitano s. J Clin Oncol. 2023 Jan 20;41(3):460-471. doi: 10.1200/JCO.22.01423. Epub 2022 Nov 9. J Clin Oncol. 2023. PMID: 36351210 Free PMC article.
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.
Lee HM, Saw AK, Morris VK, Napolitano S, Bristow C, Srinivasan S, Peoples M, Sorokin A, Kanikarla Marie P, Schulz J, Singh AK, Terranova C, Coker O, Jain A, Kopetz S, Rai K. Lee HM, et al. Among authors: napolitano s. Clin Cancer Res. 2024 Nov 15;30(22):5166-5179. doi: 10.1158/1078-0432.CCR-24-1166. Clin Cancer Res. 2024. PMID: 39269307
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E. Vitiello PP, et al. Among authors: napolitano s. J Exp Clin Cancer Res. 2019 Jan 28;38(1):41. doi: 10.1186/s13046-019-1035-0. J Exp Clin Cancer Res. 2019. PMID: 30691487 Free PMC article.
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T. Belli V, et al. Among authors: napolitano s. J Exp Clin Cancer Res. 2019 Jun 4;38(1):236. doi: 10.1186/s13046-019-1230-z. J Exp Clin Cancer Res. 2019. PMID: 31164152 Free PMC article.
263 results